During the last session, Candel Therapeutics Inc (NASDAQ:CADL)’s traded shares were 0.78 million, with the beta value of the company hitting -1.24. At the end of the trading day, the stock’s price was $9.05, reflecting an intraday gain of 2.61% or $0.23. The 52-week high for the CADL share is $14.60, that puts it down -61.33 from that peak though still a striking 85.19% gain since the share price plummeted to a 52-week low of $1.34. The company’s market capitalization is $402.50M, and the average intraday trading volume over the past 10 days was 0.85 million shares, and the average trade volume was 3.95 million shares over the past three months.
Candel Therapeutics Inc (CADL) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. CADL has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.19.
Candel Therapeutics Inc (NASDAQ:CADL) trade information
Candel Therapeutics Inc (CADL) registered a 2.61% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 2.61% in intraday trading to $9.05, hitting a weekly high. The stock’s 5-day price performance is 4.50%, and it has moved by 13.13% in 30 days. Based on these gigs, the overall price performance for the year is 402.78%. The short interest in Candel Therapeutics Inc (NASDAQ:CADL) is 2.64 million shares and it means that shorts have 2.07 day(s) to cover.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -46.75%. While earnings are projected to return -11.83% in 2025.
CADL Dividends
Candel Therapeutics Inc is due to release its next quarterly earnings in March. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Candel Therapeutics Inc (NASDAQ:CADL)’s Major holders
Candel Therapeutics Inc insiders own 19.94% of total outstanding shares while institutional holders control 39.99%, with the float percentage being 49.95%. NORTHPOND VENTURES, LLC is the largest shareholder of the company, while 87.0 institutions own stock in it. As of 2024-06-30, the company held over 1.94 million shares (or 6.477% of all shares), a total value of $12.0 million in shares.
The next largest institutional holding, with 0.82 million shares, is of BLACKROCK INC.’s that is approximately 2.819% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $5.1 million.
Also, the Mutual Funds coming in first place with the largest holdings of Candel Therapeutics Inc (CADL) shares are Fidelity Select Portfolios – Biotechnology and iShares Russell 2000 ETF . Data provided on Dec 31, 2024 indicates that Fidelity Select Portfolios – Biotechnology owns about 3.92 shares. This amounts to just over 12.06 percent of the company’s overall shares, with a $35.44 million market value. The same data shows that the other fund manager holds slightly less at 555.0, or about 1.71% of the stock, which is worth about $5.02 million.
